Table 2 Rates of discontinuation and non-publication of orthopaedic oncology clinical trials
From: Discontinuation and nonpublication of clinical trials in orthopaedic oncology
Characteristic | Discontinued trials (n = 25) | Unpublished trials (n = 18) | ||
|---|---|---|---|---|
No. (%) | AOR (95%CI) | No. (%) | AOR (95%CI) | |
Intervention | ||||
 Pharmaceutical | 23 (92.0%) | 1 [Ref] | 8 (44%) | 1 [Ref] |
 Behavioral/dietary | 0 (0%) | – | 4 (22%) | 1.6 (0.64–4.18) |
 Device | 1 (4.0%) | 1.08 (0.78–2.35) | 2 (11.1%) | 1.03 (.65–4.57) |
 Procedure | 1 (4.0%) | 1.12 (0.63–1.26) | 4 (22%) | .85 (.57–1.93) |
Funding | ||||
 NIH | 10 (40.0%) | 1 [Ref] | 4 (19.05%) | 1 [Ref] |
 Industry | 13 (52.0%) | 0.45 (0.29–1.24) | 8 (52.38%) | 0.49 (0.36–1.94) |
 Mixed | 0 (0%) | – | 2 (9.52%) | 0.62 (0.27–1.87) |
 Other | 2 (8.0%) | 0.48 (0.4–1.21) | 4 (19.05%) | 0.74 (0.46–2.78) |
Enrollment | ||||
 < 261 | 17 (68.0%) | 1 [Ref] | 8 (44.4%) | 1 [Ref] |
 ≥ 261 | 8 (32.0%) | 0.85 (0.42–0.95) | 10 (55.6%) | 0.19 (0.13–0.47) |